<DOC>
	<DOCNO>NCT00908154</DOCNO>
	<brief_summary>GSK1014802 use-dependent sodium channel blocker effective anticonvulsant animal model . This study conduct obtain information regard safety , tolerability pharmacokinetics repeat dos GSK1014802 administer 28 day healthy male female subject . In addition , effect food pharmacokinetics GSK1014802 investigate .</brief_summary>
	<brief_title>Safety , Tolerability Pharmacokinetics Repeat Doses GSK1014802 .</brief_title>
	<detailed_description>GSK1014802 use-dependent sodium channel blocker effective anticonvulsant animal model . This study conduct obtain information regard safety , tolerability pharmacokinetics repeat dos GSK1014802 administer 28 day healthy male female subject . In addition , effect food pharmacokinetics GSK1014802 investigate .</detailed_description>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Sodium Channel Blockers</mesh_term>
	<mesh_term>Diuretics , Potassium Sparing</mesh_term>
	<criteria>Healthy determine responsible physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . Male female ( nonchild bear potential ) subject age 18 55 year . A female subject eligible participate nonchildbearing potential . Male subject must agree use acceptable form contraception . Body weight â‰¥ 50 kg BMI within range 19 29.9 kg/m2 ( inclusive ) Capable give write informed consent , include compliance requirement restriction list consent form . QTcB QTcF &lt; 450 msec ; QTc &lt; 480 msec subject Bundle Branch Block . The subject positive prestudy drug/alcohol screen . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen A positive test HIV antibody . History regular alcohol consumption within 6 month study define average weekly intake great 21 unit average daily intake great 3 unit ( male ) , defined average weekly intake great 14 unit average daily intake great 2 unit ( female ) . Current past history symptomatic orthostatic hypotension history unexplained vasovagal episode ( ) . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives ( 60 h ) twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female . Lactating female . Unwillingness inability follow procedure outline protocol . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . . Consumption red wine , seville orange , grapefruit grapefruit juice and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juices 7 day prior first dose study medication . History know suspected seizure , include infantile febrile , unexplained significant recent loss consciousness history significant head trauma loss consciousness family history ( first degree relative ) epilepsy seizure ( fit ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>sodium channel blocker</keyword>
	<keyword>bipolar disorder</keyword>
	<keyword>repeat dose</keyword>
</DOC>